Join our daily newsletter At The Bell to receive exclusive market insights
Biopharmaceutical company Dimerix Ltd (ASX:DXB) has partnered with Japanese company FUSO to progress the development and commercialisation of its drug DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease.
According to the exclusive development and license agreement, FUSO Pharmaceutical Industries Ltd will acquire exclusive rights to develop, register, and commercialise DMX-200 in Japan, taking on all clinical trial costs within the country.
The candidate is currently in global Phase 3 clinical development, with a blinded interim analysis expected in August 2025.
Dimerix – which retains all commercialisation rights for DMX-200 in all territories other
than those covered by its agreements with FUSO, Advanz Pharma, and Taiba – will receive up to ¥10.5 billion (A$1071M) in upfront, development, and sales milestone payments, as well as through royalties.
CEO and managing director Dr Nina Webster said Dimerix was pleased to enter this partnership for the development of the candidate in Japan.
“FUSO brings a wealth of experience in pharmaceutical development and sales and marketing across Japan, and with a proven record in sales and marketing products for patients with renal disease,” she said.
“This partnership reflects a confidence not only in the significant potential for DMX-200 in FSGS patients but also in Dimerix’s capabilities in the development of DMX-200.
“FUSO’s expertise and resources will be invaluable in supporting Dimerix to advance our shared goal of developing and commercialising DMX-200 and bringing hope to those patients desperately in need of treatment options.”
Dimerix shares rose on the news, and at 10:35 AEDT, they were trading at 42.5 cents – a rise of 19.72% since the market opened.
Join the discussion: See what HotCopper users are saying about Dimerix Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
